Clinical-stage oncology company Nuview Life Sciences Inc. is developing a cancer diagnostic test and treatment delivery system that could reduce the need for costly, less accurate tests and surgical biopsies. The binary – yes/no – test employs a proprietary peptide construct, NV-VPAC1, that targets a specific receptor, called vasoactive intestinal peptide receptor type 1 (VPAC1), that is overexpressed on the surface of cancer cells.

PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. is acquiring Scintec Diagnostics GmbH subsidiary Therapharm GmbH in a deal worth AU$33 million (US$24.24 million) plus royalties. Zug, Switzerland-based Therapharm has developed a portfolio of radiolabeled diagnostic and therapeutic products, and the deal brings Telix a new targeting asset in hematology, Telix CEO Chris Behrenbruch told analysts during a Dec. 1 conference call.